Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

  • Technology appraisal guidance
  • TA195
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the West Midlands Health Technology Assessment Collaboration:

  • Malottki K., Barton P., et. al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation (November 2009)

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Abbott

  • Bristol-Myers Squibb

  • Roche

  • Schering-Plough

  • Pfizer

II) Professional/specialist and patient/carer groups:

  • Arthritis and Musculoskeletal Alliance (ARMA)

  • Arthritis Care

  • British Health Professionals in Rheumatology

  • British Society for Rheumatology

  • National Rheumatoid Arthritis Society

  • Primary Care Rheumatology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • South Asian Health Foundation

III) Other consultees:

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • Arthritis Research Campaign

  • AstraZeneca UK

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline

  • Medac UK

  • NHS Quality Improvement Scotland

  • Novartis

  • Roche Products

  • Sanofi Aventis

  • UCB Pharma

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor by attending the initial Committee discussion and/or providing written evidence to the Committee. They were invited to comment on the ACD.

  • Dr Chris Deighton, Consultant Rheumatologist, Derbyshire Royal Infirmary, nominated by the British Society for Rheumatology – clinical specialist

  • Dr Frank McKenna, Consultant Rheumatologist, Trafford General Hospital, nominated by the British Society for Rheumatology – clinical specialist

  • Ailsa Bosworth, Chief Executive Officer, National Rheumatoid Arthritis Society, nominated by the National Rheumatoid Arthritis Society – patient expert

  • Jean Burke, nominated by the National Rheumatoid Arthritis Society – patient expert

D. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Abbott

  • Bristol-Myers Squibb

  • Roche

  • Schering-Plough

  • Pfizer